Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | QPCT | Q16769 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 7/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 7/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 6/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000881 | 0.88 | IDO1 (0.60) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL27834213 | 0.82 | RIPK1 (0.63) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL21154204 | 0.82 | RAB9A (0.57) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL21588479 | 0.82 | SMN1; SMN2 (0.50) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL7848214 | 0.81 | NPC1 (0.64) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| Bromide SCHEMBL11217271 | 0.81 | MAPT (0.59) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL13932689 | 0.79 | RAB9A (0.57) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL28147016 | 0.79 | NPC1 (0.60) | MAPTNPC1ALDH1A1LMNAKDM4E | |
| SCHEMBL13508874 | 0.78 | MAP3K5 (0.49) | NPC1ALDH1A1RAB9ASMN1; SMN2QPCT | |
| SCHEMBL21154639 | 0.78 | ALDH1A1 (0.38) | MAPTNPC1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | MAPT 1/4885NPC1 290/4885ALDH1A1 3543/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | MAPT 1/4885NPC1 144/4885ALDH1A1 2468/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | MAPT 1/4885NPC1 290/4885ALDH1A1 3543/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | MAPT 1/4885NPC1 325/4885ALDH1A1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.